Tony Marchand, Cédric Pastoret, Gandhi Damaj, Angélique Lebouvier, Charles Herbaux, Aline Moignet, Miguel Pavlosky, Astrid Pavlosky, Anaise Blouet, Martin Eloit, Vincent Launay, Pierre Lebreton, Aspasia Stamatoullas, Christer Nilsson, Marlène Ochmann, Juliette Prola, Thierry Lamy
Large granular lymphocytic (LGL) leukaemia is a rare chronic lymphoproliferative disorder characterized by an expansion of cytotoxic T or NK cells. Despite a usually indolent evolution, most patients will require a treatment over the course of the disease because of cytopenia or symptomatic associated autoimmune disorders. First-line treatment is based on immunosuppressive agents, namely cyclophosphamide, methotrexate and ciclosporin. However, relapses are frequent, and there is no consensus on the management of relapsed/refractory patients...
April 19, 2024: British Journal of Haematology